Herbert Tilg

List of Publications by Year
in descending order

140 papers	23,853 citations	16411 64 h-index	11030 137 g-index
147 all docs	147 docs citations	147 times ranked	32112 citing authors

#	Article	IF	Citations
1	Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nature Reviews Immunology, 2006, 6, 772-783.	10.6	2,618
2	Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology, 2010, 52, 1836-1846.	3.6	1,857
3	Intestinal permeability â€“ a new target for disease prevention and therapy. BMC Gastroenterology, 2014, 14, 189.	0.8	1,187
4	Cytokines in Alcoholic and Nonalcoholic Steatohepatitis. New England Journal of Medicine, 2000, 343, 1467-1476.	13.9	874
5	Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut, 2017, 66, 1138-1153.	6.1	807
6	European consensus conference on faecal microbiota transplantation in clinical practice. Gut, 2017, 66, 569-580.	6.1	793
7	Gut microbiome, obesity, and metabolic dysfunction. Journal of Clinical Investigation, 2011, 121, 2126-2132.	3.9	703
8	NAFLD and diabetes mellitus. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 32-42.	8.2	687
9	Gut microbiome and health: mechanistic insights. Gut, 2022, 71, 1020-1032.	6.1	661
10	Inflammatory Mechanisms in the Regulation of Insulin Resistance. Molecular Medicine, 2008, 14, 222-231.	1.9	615
11	The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 10, 239-254.	0.6	577
12	The intestinal microbiota fuelling metabolic inflammation. Nature Reviews Immunology, 2020, 20, 40-54.	10.6	573
13	The Intestinal Microbiota in Colorectal Cancer. Cancer Cell, 2018, 33, 954-964.	7.7	543
14	A guiding map for inflammation. Nature Immunology, 2017, 18, 826-831.	7.0	506
15	Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease. Gut, 2018, 67, 891-901.	6.1	458
16	Gut microbiome and liver diseases. Gut, 2016, 65, 2035-2044.	6.1	443
17	Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends in Endocrinology and Metabolism, 2008, 19, 371-379.	3.1	402
18	NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut, 2020, 69, 1691-1705.	6.1	369

#	Article	IF	Citations
19	Nonalcoholic Fatty Liver Disease: Cytokine-Adipokine Interplay and Regulation of Insulin Resistance. Gastroenterology, 2006, 131, 934-945.	0.6	325
20	International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut, 2019, 68, 2111-2121.	6.1	290
21	Food, Immunity, and the Microbiome. Gastroenterology, 2015, 148, 1107-1119.	0.6	278
22	Faecal calprotectin indicates intestinal inflammation in COVID-19. Gut, 2020, 69, 1543-1544.	6.1	247
23	Interleukinâ€1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology, 2016, 64, 955-965.	3.6	246
24	Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut, 2021, 70, 962-969.	6.1	238
25	Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH. Nature, 2021, 592, 444-449.	13.7	233
26	Association of the COVID-19 pandemic with Internet Search Volumes: A Google TrendsTM Analysis. International Journal of Infectious Diseases, 2020, 95, 192-197.	1.5	218
27	Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor Â expression. Gut, 2010, 59, 1259-1264.	6.1	214
28	Blockade of receptor activator of nuclear factor-Î°B (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nature Medicine, 2013, 19, 358-363.	15.2	211
29	Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 425-439.	8.2	207
30	Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. The Lancet Gastroenterology and Hepatology, 2021, 6, 578-588.	3.7	206
31	Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clinical Science, 2008, 114, 275-288.	1.8	204
32	Circulating MicroRNA-122 Is Associated With the Risk of New-Onset Metabolic Syndrome and Type 2 Diabetes. Diabetes, 2017, 66, 347-357.	0.3	199
33	Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade. Hepatology, 2021, 73, 833-842.	3.6	188
34	IL-37 protects against obesity-induced inflammation and insulin resistance. Nature Communications, 2014, 5, 4711.	5.8	186
35	Gut microbiome, liver immunology, and liver diseases. Cellular and Molecular Immunology, 2021, 18, 4-17.	4.8	182
36	Obesity and the Microbiota. Gastroenterology, 2009, 136, 1476-1483.	0.6	172

#	Article	IF	Citations
37	COVID-19 and the gastrointestinal tract: more than meets the eye. Gut, 2020, 69, 973-974.	6.1	167
38	Calprotectin: from biomarker to biological function. Gut, 2021, 70, 1978-1988.	6.1	163
39	Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut, 2022, 71, 156-162.	6.1	162
40	From NAFLD to MAFLD: when pathophysiology succeeds. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 387-388.	8.2	157
41	Higher spermidine intake is linked to lower mortality: a prospective population-based study. American Journal of Clinical Nutrition, 2018, 108, 371-380.	2.2	150
42	Adipose and Liver Expression of Interleukin (IL)-1 Family Members in Morbid Obesity and Effects of Weight Loss. Molecular Medicine, 2011, 17, 840-845.	1.9	147
43	Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nature Metabolism, 2021, 3, 1596-1607.	5.1	147
44	Postacute COVID-19 is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases. Gastroenterology, 2022, 163, 495-506.e8.	0.6	144
45	Nonalcoholic fatty liver disease and hepatocellular carcinoma. Metabolism: Clinical and Experimental, 2016, 65, 1151-1160.	1.5	143
46	Dietary lipids fuel GPX4-restricted enteritis resembling Crohnâ€™s disease. Nature Communications, 2020, 11, 1775.	5.8	143
47	Management strategies in alcoholic liver disease. Nature Reviews Gastroenterology & Hepatology, 2007, 4, 24-34.	1.7	137
48	Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. Journal of Hepatology, 2009, 51, 765-777.	1.8	136
49	Global multi-stakeholder endorsement of the MAFLD definition. The Lancet Gastroenterology and Hepatology, 2022, 7, 388-390.	3.7	135
50	Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut, 2022, 71, 778-788.	6.1	132
51	How to modulate inflammatory cytokines in liver diseases. Liver International, 2006, 26, 1029-1039.	1.9	114
52	Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. Gut, 2020, 69, 1555-1563.	6.1	110
53	Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. The Lancet Gastroenterology and Hepatology, 2020, 5, 430-432.	3.7	108
54	Obesity, Metabolic Syndrome, and Microbiota. Journal of Clinical Gastroenterology, 2010, 44, S16-S18.	1.1	98

#	Article	IF	Citations
55	Dietary spermidine improves cognitive function. Cell Reports, 2021, 35, 108985.	2.9	98
56	Adipose tissue and liver expression of SIRT1, 3, and 6 increase after extensive weight loss in morbid obesity. Journal of Hepatology, 2013, 59, 1315-1322.	1.8	92
57	Type I interferon signalling in the intestinal epithelium affects Paneth cells, microbial ecology and epithelial regeneration. Gut, 2014, 63, 1921-1931.	6.1	84
58	Pathways of liver injury in alcoholic liver disease. Journal of Hepatology, 2011, 55, 1159-1161.	1.8	83
59	Current therapies and new developments in NASH. Gut, 2022, 71, 2123-2134.	6.1	82
60	Incidence of Bloodstream Infections, Length of Hospital Stay, and Survival in Patients With RecurrentClostridioides difficileInfection Treated With Fecal Microbiota Transplantation or Antibiotics. Annals of Internal Medicine, 2019, 171, 695.	2.0	81
61	Lipocalin 2 drives neutrophilic inflammation in alcoholic liver disease. Journal of Hepatology, 2016, 64, 872-880.	1.8	80
62	Association between nonâ€alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated metaâ€analysis. Liver International, 2019, 39, 758-769.	1.9	75
63	Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial. Lancet Respiratory Medicine,the, 2021, 9, 863-872.	5.2	75
64	Gut Dysfunction and Non-alcoholic Fatty Liver Disease. Frontiers in Endocrinology, 2019, 10, 611.	1.5	69
65	Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk. PLoS ONE, 2016, 11, e0167146.	1.1	68
66	B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19. EBioMedicine, 2021, 70, 103539.	2.7	67
67	A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group. United European Gastroenterology Journal, 2021, 9, 229-247.	1.6	66
68	Systemic inflammation as fuel for acute liver injury in COVID-19. Digestive and Liver Disease, 2021, 53, 158-165.	0.4	63
69	Adipose type I interferon signalling protects against metabolic dysfunction. Gut, 2018, 67, 157-165.	6.1	61
70	Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltosideâ€"a systematic review and metaâ€analysis. British Journal of Clinical Pharmacology, 2021, 87, 2256-2273.	1.1	61
71	Mechanisms behind the link between obesity and gastrointestinal cancers. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 599-610.	1.0	58
72	Heterozygosity for the alphaâ€1â€antitrypsin Z allele in cirrhosis is associated with more advanced disease. Liver Transplantation, 2018, 24, 744-751.	1.3	58

#	Article	IF	Citations
73	Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 781-793.	3.7	58
74	Lipocalinâ€2 ensures host defense against Salmonella Typhimurium by controlling macrophage iron homeostasis and immune response. European Journal of Immunology, 2015, 45, 3073-3086.	1.6	53
75	COVID-19 and liver disease. Gut, 2022, 71, 2350-2362.	6.1	48
76	Nuclear Receptors Regulate Intestinal Inflammation in the Context of IBD. Frontiers in Immunology, 2019, 10, 1070.	2.2	47
77	Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name. Metabolism: Clinical and Experimental, 2020, 113, 154413.	1.5	45
78	Intravenous iron supplementation therapy. Molecular Aspects of Medicine, 2020, 75, 100862.	2.7	44
79	Faecal Biomarkers in Inflammatory Bowel Diseases: Calprotectin Versus Lipocalin-2â€”a Comparative Study. Journal of Crohn's and Colitis, 2021, 15, 43-54.	0.6	40
80	Hypophosphatemia after intravenous iron therapy: Comprehensive review of clinical findings and recommendations for management. Bone, 2022, 154, 116202.	1.4	40
81	Indications for liver transplantation in adults. Wiener Klinische Wochenschrift, 2016, 128, 679-690.	1.0	39
82	Prebiotic Effects of Partially Hydrolyzed Guar Gum on the Composition and Function of the Human Microbiotaâ€”Results from the PAGODA Trial. Nutrients, 2020, 12, 1257.	1.7	39
83	Excellent postâ€transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy. Liver International, 2016, 36, 688-695.	1.9	38
84	Diet and Intestinal Immunity. New England Journal of Medicine, 2012, 366, 181-183.	13.9	36
85	Metabolomic analysisâ€”Addressing NMR and LC-MS related problems in human feces sample preparation. Clinica Chimica Acta, 2019, 489, 169-176.	0.5	35
86	NAFLD and extrahepatic cancers: have a look at the colon. Gut, 2011, 60, 745-746.	6.1	32
87	Modulation of Liver Inflammation and Fibrosis by Interleukin-37. Frontiers in Immunology, 2021, 12, 603649.	2.2	30
88	Pancreasâ€“Microbiota Cross Talk in Health and Disease. Annual Review of Nutrition, 2019, 39, 249-266.	4.3	28
89	Update on nonalcoholic fatty liver disease: genes involved in nonalcoholic fatty liver disease and associated inflammation. Current Opinion in Clinical Nutrition and Metabolic Care, 2010, 13, 391-396.	1.3	27
90	Liver tissue microbiome in NAFLD: next step in understanding the gutâ€“liver axis?. Gut, 2020, 69, 1373-1374.	6.1	27

#	Article	IF	Citations
91	Dynamics of Bile Acid Profiles, GLP-1, and FGF19 After Laparoscopic Gastric Banding. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2974-2984.	1.8	24
92	Preoperative Assessment of Muscle Mass Using Computerized Tomography Scans to Predict Outcomes Following Orthotopic Liver Transplantation. Transplantation, 2019, 103, 2506-2514.	0.5	24
93	PUFA-Induced Metabolic Enteritis as a Fuel for Crohnâ€™s Disease. Gastroenterology, 2022, 162, 1690-1704.	0.6	24
94	Decline in acute upper gastrointestinal bleeding during COVID-19 pandemic after initiation of lockdown in Austria. Endoscopy, 2020, 52, 1036-1038.	1.0	23
95	NAFLD-related mortality: simple hepatic steatosis is not as â€˜benignâ€™ as thought. Gut, 2021, 70, 1212-1213.	6.1	22
96	Vedolizumab, a humanized mAb against the Î±4Î²7 integrin for the potential treatment of ulcerative colitis and Crohn's disease. Current Opinion in Investigational Drugs, 2010, 11, 1295-304.	2.3	22
97	Why we need to curb the emerging worldwide epidemic of nonalcoholic fatty liver disease. Nature Metabolism, 2019, 1, 1027-1029.	5.1	21
98	Micro- and Mycobiota Dysbiosis in Pancreatic Ductal Adenocarcinoma Development. Cancers, 2021, 13, 3431.	1.7	21
99	Liver stiffness by transient elastography accompanies illness severity in COVID-19. BMJ Open Gastroenterology, 2020, 7, e000445.	1.1	20
100	Dimethyl fumarate ameliorates hepatic inflammation in alcohol related liver disease. Liver International, 2020, 40, 1610-1619.	1.9	20
101	XIAP restrains TNF-driven intestinal inflammation and dysbiosis by promoting innate immune responses of Paneth and dendritic cells. Science Immunology, 2021, 6, eabf7235.	5.6	17
102	Metabolic recovery after weight loss surgery is reflected in serum microRNAs. BMJ Open Diabetes Research and Care, 2020, 8, e001441.	1.2	15
103	Adipocyte GPX4 protects against inflammation, hepatic insulin resistance and metabolic dysregulation. International Journal of Obesity, 2022, 46, 951-959.	1.6	15
104	Association between non-alcoholic fatty liver disease and impaired cardiac sympathetic/parasympathetic balance in subjects with and without type 2 diabetesâ€”The Cooperative Health Research in South Tyrol (CHRIS)-NAFLD sub-study. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 3464-3473.	1.1	14
105	Uterine microbiota plasticity during the menstrual cycle: Differences between healthy controls and patients with recurrent miscarriage or implantation failure. Journal of Reproductive Immunology, 2022, 151, 103634.	0.8	14
106	Weight loss induced by bariatric surgery restores adipose tissue <scp>PNPLA</scp>3 expression. Liver International, 2017, 37, 299-306.	1.9	13
107	Weight Loss Induced by Bariatric Surgery Restricts Hepatic GDF15 Expression. Journal of Obesity, 2018, 2018, 1-6.	1.1	13
108	A role for IL-1 inhibitors in the treatment of non-alcoholic fatty liver disease (NAFLD)?. Expert Opinion on Investigational Drugs, 2020, 29, 103-106.	1.9	13

#	Article	IF	Citations
109	Interleukin-11 drives human and mouse alcohol-related liver disease. Gut, 2023, 72, 168-179.	6.1	13
110	Increased Fecal Neopterin Parallels Gastrointestinal Symptoms in COVID-19. Clinical and Translational Gastroenterology, 2021, 12, e00293.	1.3	12
111	Short bowel syndrome: searching for the proper diet. European Journal of Gastroenterology and Hepatology, 2008, 20, 1061-1063.	0.8	10
112	Prescription of oral antidiabetic drugs in Tyrol â€“ Data from the Tyrol diabetes registry 2012â€“2015. Wiener Klinische Wochenschrift, 2017, 129, 46-51.	1.0	9
113	Live Confocal Imaging as a Novel Tool to Assess Liver Quality: Insights From a Murine Model. Transplantation, 2020, 104, 2528-2537.	0.5	9
114	MRIâ€Based Iron Phenotyping and Patient Selection for Nextâ€Generation Sequencing of Nonâ€“Homeostatic Iron Regulator Hemochromatosis Genes. Hepatology, 2021, 74, 2424-2435.	3.6	8
115	The Need to Update Endpoints and Outcome Analysis in the Rapidly Changing Field of Liver Transplantation. Transplantation, 2022, 106, 938-949.	0.5	8
116	Gastric banding-associated weight loss diminishes hepatic Tsukushi expression. Cytokine, 2020, 133, 155114.	1.4	7
117	Cell-autonomous Hedgehog signaling controls Th17 polarization and pathogenicity. Nature Communications, 2022, 13, .	5.8	7
118	Relevance ofTNF-Î± gene polymorphisms in nonalcoholic fatty liver disease. Expert Review of Gastroenterology and Hepatology, 2011, 5, 155-158.	1.4	6
119	Too much fat for the gut's microbiota. Gut, 2012, 61, 474-475.	6.1	6
120	Disease burden of hepatitis C in the Austrian state of Tyrol â€“ Epidemiological data and model analysis to achieve elimination by 2030. PLoS ONE, 2018, 13, e0200750.	1.1	6
121	Coronary atherosclerosis profile in patients with end-stage liver disease prior to liver transplantation due to alcoholic fatty liver: a coronary CTA study. European Radiology, 2021, 31, 494-503.	2.3	6
122	Alpha-1 antitrypsin governs alcohol-related liver disease in mice and humans. Gut, 2021, 70, 585-594.	6.1	6
123	Reassessment of Relevance and Predictive Value of Parameters Indicating Early Graft Dysfunction in Liver Transplantation: AST Is a Weak, but Bilirubin and INR Strong Predictors of Mortality. Frontiers in Surgery, 2021, 8, 693288.	0.6	6
124	Synonymous mutation in adenosine triphosphatase copperâ€transporting beta causes enhanced exon skipping in Wilson disease. Hepatology Communications, 2022, 6, 1611-1619.	2.0	6
125	Shortâ€term effects of dapagliflozin on insulin sensitivity, postprandial glucose excursion and ketogenesis in type 1 diabetes mellitus: A randomized, placeboâ€controlled, double blind, crossâ€over pilot study. Diabetes, Obesity and Metabolism, 2018, 20, 2685-2689.	2.2	5
126	SARS-CoV-2 vaccines and donor recruitment for FMT. The Lancet Gastroenterology and Hepatology, 2021, 6, 264-266.	3.7	5

#	Article	IF	Citations
127	Iron Matryoshkaâ€"Haemochromatosis nested in Ferroportin Disease?. Liver International, 2019, 39, 1014-1015.	1.9	4
128	Highly Elevated Plasma Î³â€Glutamyltransferase Elevations: A Trait Caused by Î³â€Glutamyltransferase 1 Transmembrane Mutations. Hepatology, 2020, 71, 1124-1127.	3.6	4
129	Apolipoprotein A5 controls fructose-induced metabolic dysregulation in mice. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 972-978.	1.1	3
130	Hepatic Meteorin-like and KrÃ¼ppel-like Factor 3 are Associated with Weight Loss and Liver Injury. Experimental and Clinical Endocrinology and Diabetes, 2022, 130, 406-414.	0.6	3
131	Is Heterozygosity for the Alpha-1 Antitrypsin Risk Allele Piâ^—MZ a Disease Modifier or Genetic Risk Factor?. Gastroenterology, 2020, 159, 433-434.	0.6	2
132	Using Infodemiology Metrics to Assess Public Interest in Liver Transplantation: Google Trends Analysis. Journal of Medical Internet Research, 2021, 23, e21656.	2.1	2
133	Treatment With Î±-1-Antitrypsin for Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease. Transplantation, 2016, 100, e158-e159.	0.5	1
134	Reply to Gostner and Fuchs. American Journal of Clinical Nutrition, 2019, 109, 218-219.	2.2	1
135	Cloak and dagger â€•secondary hemophygocytic lymphohistiocytosis caused by intravenous autoinfection. American Journal of Hematology, 2020, 95, 330-332.	2.0	1
136	Is There Decreasing Public Interest in Renal Transplantation? A Google TrendsTM Analysis. Journal of Clinical Medicine, 2020, 9, 1048.	1.0	1
137	Liver microbes controlling immunity: Facts and pitfalls. Cell Metabolism, 2022, 34, 510-512.	7.2	1
138	Reply. Liver Transplantation, 2019, 25, 344-345.	1.3	0
139	Reply. Liver Transplantation, 2019, 25, 1287-1288.	1.3	0
140	Maintenance of Telomere Length in Peripheral Blood CD4+CD25+ Regulatory T-Cells of Cancer Patients Despite Active Proliferation.. Blood, 2005, 106, 3309-3309.	0.6	0